Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes.

Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, Good C, Restrepo MI, Downs JR, Frei CR, Fine MJ.

Clin Infect Dis. 2012 Dec;55(11):1466-73. doi: 10.1093/cid/cis733. Epub 2012 Aug 23.

2.

The association of cardioprotective medications with pneumonia-related outcomes.

Wu A, Good C, Downs JR, Fine MJ, Pugh MJ, Anzueto A, Mortensen EM.

PLoS One. 2014 Jan 28;9(1):e85797. doi: 10.1371/journal.pone.0085797. eCollection 2014.

3.

Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia.

Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, Anzueto A, Pugh JA.

Eur Respir J. 2008 Mar;31(3):611-7. Epub 2007 Oct 24.

4.

Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.

Butt DA, Mamdani M, Gomes T, Lix L, Lu H, Tu K; Hypertension Outcome, Surveillance Team.

J Bone Miner Res. 2014 Nov;29(11):2483-8. doi: 10.1002/jbmr.2271.

5.

Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.

Li EC, Heran BS, Wright JM.

Cochrane Database Syst Rev. 2014 Aug 22;(8):CD009096. doi: 10.1002/14651858.CD009096.pub2. Review.

PMID:
25148386
6.
7.

The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality.

Ardehali R, Leeper NJ, Wilson AM, Heidenreich PA.

J Heart Valve Dis. 2012 May;21(3):337-43.

8.

The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study.

Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, Lee HH, Chung W, Jung JY.

Am J Kidney Dis. 2012 Oct;60(4):576-82. doi: 10.1053/j.ajkd.2012.04.017. Epub 2012 May 31. Erratum in: Am J Kidney Dis. 2013 May;61(5):849.

PMID:
22658321
9.

Impact of statins and ACE inhibitors on mortality after COPD exacerbations.

Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, Anzueto A.

Respir Res. 2009 Jun 3;10:45. doi: 10.1186/1465-9921-10-45.

10.

Preadmission use of renin-angiotensin blockers and rupture of abdominal aortic aneurysm: a nationwide, population-based study.

Wemmelund H, Høgh A, Hundborg HH, Johnsen SP, Lindholt JS.

Pharmacoepidemiol Drug Saf. 2016 Feb;25(2):141-50. doi: 10.1002/pds.3913. Epub 2015 Nov 17.

PMID:
26817783
11.
12.

Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.

Shih CJ, Chen HT, Kuo SC, Li SY, Lai PH, Chen SC, Ou SM, Chen YT.

CMAJ. 2016 May 17;188(8):E148-57. doi: 10.1503/cmaj.150771. Epub 2016 Mar 21.

13.

Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.

Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM.

J Am Coll Cardiol. 2006 Jun 20;47(12):2554-60. Epub 2006 May 2.

14.

Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis.

Shah M, Jain AK, Brunelli SM, Coca SG, Devereaux PJ, James MT, Luo J, Molnar AO, Mrkobrada M, Pannu N, Parikh CR, Paterson M, Shariff S, Wald R, Walsh M, Whitlock R, Wijeysundera DN, Garg AX.

BMC Nephrol. 2014 Apr 2;15:53. doi: 10.1186/1471-2369-15-53.

15.

Potential mechanisms of AT1 receptor blockers on reducing pneumonia-related mortality.

Nahmod KA, Nahmod VE, Szvalb AD.

Clin Infect Dis. 2013 Apr;56(8):1193-4. doi: 10.1093/cid/cit007. Epub 2013 Jan 11. No abstract available.

PMID:
23315319
16.

Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.

Liu CL, Shau WY, Chang CH, Wu CS, Lai MS.

J Epidemiol. 2013 Sep 5;23(5):344-50. Epub 2013 Aug 3.

17.

Contraceptive methods and informed consent among women receiving medications with potential for adverse fetal effects: a Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) region study.

Force RW, Keppel GA, Guirguis-Blake J, Gould DA, Vincent C, Chunchu K, Monger RM, Holmes JT, Cauffield J, Baldwin LM.

J Am Board Fam Med. 2012 Sep-Oct;25(5):661-8.

18.

Comparing individual angiotensin-converting enzyme inhibitors with losartan in the risk of hospitalization for pneumonia and related mortality: a nationwide cohort study.

Chang CH, Lin JW, Ruan SY, Lee YC, Wu LC, Lin MS, Lai MS.

J Hypertens. 2015 Mar;33(3):634-42; discussion 642-3. doi: 10.1097/HJH.0000000000000438.

PMID:
25479025
19.

Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Sørensen GV, Ganz PA, Cole SW, Pedersen LA, Sørensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP.

J Clin Oncol. 2013 Jun 20;31(18):2265-72. doi: 10.1200/JCO.2012.43.9190. Epub 2013 May 6.

20.

A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age ≥ 65 years.

Zhang Y, Fonarow GC, Sanders PW, Farahmand F, Allman RM, Aban IB, Love TE, Levesque R, Kilgore ML, Ahmed A.

Am J Cardiol. 2011 Nov 15;108(10):1443-8. doi: 10.1016/j.amjcard.2011.06.066. Epub 2011 Sep 3.

Supplemental Content

Support Center